Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) was the target of a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 61,079 shares, a growth of 152.8% from the July 15th total of 24,157 shares. Currently, 0.5% of the company’s stock are sold short. Based on an average daily volume of 359,826 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Trading of Biofrontera

An institutional investor recently raised its position in Biofrontera stock. Geode Capital Management LLC grew its position in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 65,677 shares of the company’s stock after buying an additional 23,074 shares during the period. Geode Capital Management LLC owned about 0.56% of Biofrontera worth $37,000 as of its most recent SEC filing. Institutional investors own 10.08% of the company’s stock.

Biofrontera Stock Up 3.2%

NASDAQ BFRI traded up $0.04 during trading hours on Friday, reaching $1.30. 972,630 shares of the company traded hands, compared to its average volume of 388,241. The stock has a market capitalization of $16.64 million, a PE ratio of -2.89 and a beta of 0.78. The company has a current ratio of 1.20, a quick ratio of 1.09 and a debt-to-equity ratio of 0.78. Biofrontera has a 12 month low of $0.55 and a 12 month high of $1.40. The company has a 50 day moving average of $1.08 and a two-hundred day moving average of $0.98.

Biofrontera (NASDAQ:BFRI) last released its earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 155.98%. The company had revenue of $12.00 million during the quarter, compared to the consensus estimate of $9.50 million. As a group, equities analysts expect that Biofrontera will post -0.3 earnings per share for the current year.

Analyst Ratings Changes

BFRI has been the topic of a number of recent analyst reports. Zacks Research upgraded shares of Biofrontera from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Weiss Ratings upgraded Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Finally, Wall Street Zen upgraded Biofrontera to a “hold” rating in a research note on Saturday, July 18th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Biofrontera has an average rating of “Hold”.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.